Dexrazoxane | Iron chelator/Ferroptosis inhibitor

Available Options

Size:PriceQuantity 
10 mg$48.00
50 mg$135.00
Request Quote / Bulk / Custom Size
Product Inquiry

Dexrazoxane (24584-09-6) is an iron chelator that has been used as a cardioprotective agent employed during chemotherapy with anthraquinone drugs such as daunorubicin or doxorubicin.1 More recently it has been shown to inhibit ferroptosis. It inhibited ferroptosis in a cyclophophosphamide-induced cystitis model2 as well as in doxorubicin-induced cardiomyopathy3,4.

References/Citations:

  1. Jones et al. (2008), Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity; Expert Rev. Cardiovasc. Ther., 6 1311
  2. Mao et al. (2023), Ferroptosis contributes to cyclophosphamide-induced hemorrhagic cystitis;  Chem. Biol. Interact., 384 110701
  3. Zhang et al. (2021), Protective Effects of Dexrazoxane on Rat Ferroptosis in Doxorubicin-Induced Cardiomyopathy Through Regulating HMGB1; Front. Cardiovasc. Med., 8 685434
  4. Huang et al. (2024), Pharmacological activation of GPX4 ameliorates doxorubicin-induced cardiomyopathy; Redox Biol., 70 103024
24584-09-6, Dexrazoxane, Dexrazoxane supplier, Ferroptosis inhibitor, ICRF-187, Iron chelator, NSC169780
Alternate Name:
ICRF-187; NSC169780

Safety Data Sheet:

N/A

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Dexrazoxane (24584-09-6) is an iron chelator that has been used as a cardioprotective agent employed during chemotherapy with anthraquinone drugs such as daunorubicin or doxorubicin.1 More recently it has been shown to inhibit ferroptosis. It inhibited ferroptosis in a cyclophophosphamide-induced cystitis model2 as well as in doxorubicin-induced cardiomyopathy3,4.

References/Citations:

  1. Jones et al. (2008), Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity; Expert Rev. Cardiovasc. Ther., 6 1311
  2. Mao et al. (2023), Ferroptosis contributes to cyclophosphamide-induced hemorrhagic cystitis;  Chem. Biol. Interact., 384 110701
  3. Zhang et al. (2021), Protective Effects of Dexrazoxane on Rat Ferroptosis in Doxorubicin-Induced Cardiomyopathy Through Regulating HMGB1; Front. Cardiovasc. Med., 8 685434
  4. Huang et al. (2024), Pharmacological activation of GPX4 ameliorates doxorubicin-induced cardiomyopathy; Redox Biol., 70 103024